Calamos Advisors LLC Invests $1.08 Million in Axsome Therapeutics, Inc. (NASDAQ:AXSM)

Calamos Advisors LLC bought a new position in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 12,808 shares of the company’s stock, valued at approximately $1,084,000.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in AXSM. FMR LLC raised its position in shares of Axsome Therapeutics by 20.6% during the 3rd quarter. FMR LLC now owns 1,088,087 shares of the company’s stock worth $97,786,000 after purchasing an additional 185,951 shares during the last quarter. Geode Capital Management LLC raised its holdings in shares of Axsome Therapeutics by 2.7% in the third quarter. Geode Capital Management LLC now owns 908,459 shares of the company’s stock worth $81,659,000 after acquiring an additional 23,564 shares during the last quarter. Wellington Management Group LLP raised its holdings in shares of Axsome Therapeutics by 1.1% in the third quarter. Wellington Management Group LLP now owns 742,745 shares of the company’s stock worth $66,750,000 after acquiring an additional 8,125 shares during the last quarter. Charles Schwab Investment Management Inc. raised its holdings in shares of Axsome Therapeutics by 4.1% in the third quarter. Charles Schwab Investment Management Inc. now owns 322,596 shares of the company’s stock worth $28,992,000 after acquiring an additional 12,778 shares during the last quarter. Finally, Loomis Sayles & Co. L P raised its stake in Axsome Therapeutics by 11.0% in the 3rd quarter. Loomis Sayles & Co. L P now owns 298,586 shares of the company’s stock valued at $26,834,000 after purchasing an additional 29,497 shares during the last quarter. Institutional investors and hedge funds own 81.49% of the company’s stock.

Analysts Set New Price Targets

AXSM has been the subject of several analyst reports. StockNews.com raised shares of Axsome Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, November 20th. Robert W. Baird boosted their price target on Axsome Therapeutics from $112.00 to $116.00 and gave the company an “outperform” rating in a report on Wednesday, November 13th. Needham & Company LLC reiterated a “buy” rating and issued a $133.00 price target on shares of Axsome Therapeutics in a report on Monday, January 13th. William Blair reiterated an “outperform” rating on shares of Axsome Therapeutics in a report on Friday, January 24th. Finally, Truist Financial upped their target price on Axsome Therapeutics from $180.00 to $190.00 and gave the company a “buy” rating in a research note on Monday. One analyst has rated the stock with a hold rating and fourteen have given a buy rating to the stock. According to data from MarketBeat, Axsome Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $134.00.

Axsome Therapeutics Price Performance

Axsome Therapeutics stock opened at $114.00 on Thursday. Axsome Therapeutics, Inc. has a 52-week low of $64.11 and a 52-week high of $114.00. The firm has a fifty day moving average of $94.37 and a 200-day moving average of $91.43. The firm has a market capitalization of $5.52 billion, a P/E ratio of -17.46 and a beta of 1.05. The company has a quick ratio of 2.37, a current ratio of 2.44 and a debt-to-equity ratio of 1.97.

Axsome Therapeutics (NASDAQ:AXSM) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($1.34) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.38) by $0.04. Axsome Therapeutics had a negative net margin of 91.87% and a negative return on equity of 158.36%. The business had revenue of $104.76 million during the quarter, compared to analyst estimates of $98.71 million. During the same period last year, the business earned ($1.32) EPS. As a group, analysts predict that Axsome Therapeutics, Inc. will post -4.72 EPS for the current year.

About Axsome Therapeutics

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.